Company: APM
Filing Date: 2025-10-14
Form Type: 424B5
Source: 0001213900-25-098635
Chunk: 8

Company: Aptorum Group Ltd
Filing Date: 2025-10-14
Form: 424B5
Chunk 8
---
 syndrome, other brain health disorders, and cancer. The proprietary platform technology
developed at DiamiR and protected by over 50 issued patents is based on quantitative analysis of organ-enriched microRNAs detectable in
blood plasma. In addition to blood-based microRNA panels, as part of its biopharma services DiamiR‘s CLIA/CAP-certified laboratory
offers protein and genetic biomarker analyses for screening, patient stratification, disease and treatment monitoring.

<div align='center'>S-1</div>

Our Business We are a clinical stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company now focuses all of its efforts on R&D and therefore no longer performs any therapeutic services. While the Company may commence therapeutic services in the future, as of December 31, 2024, and the date hereof, it only operates in one segment. Our goal is to develop a broad range of novel and repurposed therapeutics and diagnostics technology across a wide range of disease/therapeutic areas. Key components of our strategy for achieving this goal include: (for details of our strategy, See “Business Overview — Our Strategy”)

| ● | Developing therapeutic and diagnostic innovations across a 
 wide range of disease/therapeutic areas;                   |

| ● | Selectively expanding our portfolio with potential products                                    
 that may be able to attain orphan drug designation and/or satisfy current unmet medical needs; |

| ● | Collaborating with leading academic institutions and CROs; |

| ● | Expanding our in-house pharmaceutical development center; |

| ● | Leveraging our management’s expertise, experience and 
 commercial networks;                                  |

| ● | Obtaining and leveraging government grants to fund project 
 development.                                               |

We have devoted a substantial portion of the proceeds from our offerings to our Lead Projects. Our Lead Projects are ALS-4 and SACT-1. In March 2023, we announced that we completed the Pre-IND discussions with the US FDA on ALS-4. In March 2023, we also announced the completion of the End of Phase 1 (EOP1) meeting of SACT-1 with the US FDA. The FDA generally agreed with the chemistry-manufacturing-control (CMC) strategy and our proposed clinical development plan for SACT-1 Phase 1/2 trials. The timing and scope of